The Latest
-
Michael Santiago/Getty Images via Getty Images
IPO windowTwo biotechs raise a combined $556M in latest spurt of IPOs
Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a stretch of large IPOs this year that collectively raised almost $3.2 billion.
-
Permission granted by QIAGEN
Sponsored by QIAGEN Digital InsightsWhat is your AI drug repurposing strategy missing?
Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Six of the biotechs that have gone public this year raised at least $300 million in their IPOs, and two surpassed $400 million — totals rarely seen since the end of the pandemic.
Updated May 1, 2026 -
Getty Images
News roundupBristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.
-
Getty Images
News roundupSummit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.
-
Courtesy of UniQure
UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy
News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an uncertain future in the U.S.
-
Maddie Meyer via Getty Images
VaccinesModerna sees revenue bump from international COVID vaccine sales
The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s vaulted its stock price in 2026.
-
Getty Images
Merck still sees ‘compelling’ outlook for Terns leukemia drug
Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
UCB’s buyout of Candid is the sector’s seventh acquisition in the last week, adding to a pace that’s turning 2026 into one of the most active years ever for biotech M&A.
Updated May 4, 2026 -
Courtesy of Eli Lilly
Obesity drugsLilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
A strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for both profit and revenue.
-
Michael M. Santiago via Getty Images
IPO windowAvalyn, in pursuit of better lung drugs, banks $300M in an IPO
The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.
-
Elizabeth Regan/BioPharma Dive
Chiesi to buy KalVista in $1.9B deal for rare disease drug
The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.
-
Courtesy of Teva Pharmaceutical
Brain drug revivalTeva nabs experimental Tourette drug in $700M Emalex buyout
A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
BeOne Medicines grabbed an option to acquire an antibody from HuaHui Health that acts on three known cancer targets: PD-1, CTLA-4 and VEGF.
Updated May 1, 2026 -
Getty Images
News roundup
FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multiple myeloma drug.
-
Getty Images
Pfizer deals extend patent life for a top-selling rare disease drug
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
-
Courtesy of Boehringer Ingelheim
Obesity drugsBoehringer dual-acting obesity shot hits mark in Phase 3 trial
Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.
-
Getty Images
Emerging biotechCoultreon banks $125M to support testing of former Galapagos immune drug
Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases.
-
Getty Images
News roundup
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.
-
Getty Images
Veradermics soars on positive data for baldness treatment
The results could support the first approval in decades for an oral medicine that can treat male pattern baldness, though the therapy will face competition from generics and over-the-counter medications.
-
Permission granted by Intellia Therapeutics
Gene editingIntellia CRISPR drug succeeds in late-stage study against rare swelling disorder
The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.
-
Permission granted by Ajax Therapeutics
Lilly to buy startup Ajax in bid for a better JAK drug
Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.
-
Getty Images
Oruka surges as long-acting psoriasis drug shows early promise
A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
-
Courtesy of Sanofi
Sanofi MS drug rejected in US gets an endorsement in Europe
Tolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions the therapy for its first regulatory approval.
-
Permission granted by Roche
Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.
-
Getty Images
FDA approves Regeneron’s hearing loss gene therapy
Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s “national priority” voucher program and will be offered to eligible patients at no cost.
